| 1 |
32407212 | Cisplatin Plus Gemcitabine as Standard of Care for Germline BRCA/PALB2-Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast? | 2020 Jul 20 |
1 |
| 2 |
30320607 | Co-operation of ABT-199 and gemcitabine in impeding DNA damage repair and inducing cell apoptosis for synergistic therapy of T-cell acute lymphoblastic leukemia. | 2019 Feb |
1 |
| 3 |
25736055 | BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer. | 2015 May |
2 |
| 4 |
25847929 | Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. | 2015 Jun 10 |
1 |
| 5 |
26180923 | BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. | 2015 Jul 28 |
3 |
| 6 |
24457564 | The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. | 2014 Mar |
2 |
| 7 |
24591771 | First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients. | 2014 |
1 |
| 8 |
25202071 | Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor. | 2014 Sep |
2 |
| 9 |
22330686 | The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. | 2012 Feb 14 |
1 |
| 10 |
23359225 | Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1. | 2012 Sep |
1 |
| 11 |
21368455 | [PARP inhibitors for cancer therapy]. | 2011 Jan |
1 |
| 12 |
19968494 | In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. | 2010 Feb |
1 |
| 13 |
20798217 | Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. | 2010 Oct 15 |
1 |
| 14 |
19002265 | Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. | 2008 |
1 |
| 15 |
17686445 | How could pharmacogenomics help improve patient survival? | 2007 Aug |
1 |
| 16 |
16807441 | Pharmacogenomics and gemcitabine. | 2006 May |
3 |